The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro

Hepatology

Volumn 56, Issue 1, 2012, Pages 9-16

  Hoppe Seyler, Karin ^a   Sauer, Peter ^b   Lohrey, Claudia ^a   Hoppe Seyler, Felix ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MANITIMUS; MITOGEN ACTIVATED PROTEIN KINASE P38; MYCOPHENOLIC ACID; TELBIVUDINE; TERIFLUNOMIDE;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; GENE SILENCING; HEPATITIS B VIRUS; IN VITRO STUDY; INTRACELLULAR SIGNALING; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; VIRUS REPLICATION;

ALKYNES; CELLS, CULTURED; ENZYME INHIBITORS; HEK293 CELLS; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MYCOPHENOLIC ACID; NITRILES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRUS REPLICATION;

EID: 84863512836     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25602     Document Type: Article

References (40)

1. Teschner S, Burst V. Leflunomide: a drug with a potential beyond rheumatology. Immunotherapy 2010; 2: 637-650.
2. Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995; 50: 861-867.
3. Kaplan MJ. FK-778 Astellas. Curr Opin Investig Drugs 2005; 6: 526-536.
4. Farasati NA, Shapiro R, Vats A, Randhawa P. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 2005; 79: 116-118.
5. Williams JW, Javaid B, Kadambi PV, Gillen D, Harland R, Thistlewaite JR, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005; 352: 1157-1158.
6. Waldman WJ, Knight DA, Lurain NS, Miller DM, Sedmak DD, Williams JW, et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 1999; 68: 814-825.
7. Kloppenburg G, de Graaf R, Grauls G, Bruggeman CA, van Hooff JP, Stassen F. FK778 attenuates cytomegalovirus-enhanced vein graft intimal hyperplasia in a rat model. Intervirology 2009; 52: 189-195.
8. Knight DA, Hejmanowski AQ, Dierksheide JE, Williams JW, Chong AS, Waldman WJ. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation 2001; 71: 170-174.
9. Schläpfer E, Fischer M, Ott P, Speck RF. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. AIDS 2003; 17: 1613-1620.
10. Dunn MC, Knight DA, Waldman WJ. Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide. Antivir Ther 2011; 16: 309-317.
11. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009; 49: S13-S21.
12. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
13. Butz K, Denk C, Fitscher B, Crnkovic-Mertens I, Ullmann A, Schröder CH, et al. Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene 2001; 20: 6579-6586.
14. Calvert J, Summers J. Two regions of an avian hepadnavirus RNA pregenome are required in cis for encapsidation. J Virol 1994; 68: 2084-2090.
15. Weber K, Bartsch U, Stocking C, Fehse B. A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Mol Ther 2008; 16: 698-706.
16. Sureau C, Romet-Lemonne JL, Mullins JI, Essex M. Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell 1986; 47: 37-47.
17. Lamberts C, Nassal M, Velhagen I, Zentgraf H, Schröder CH. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J Virol 1993; 67: 3756-3762.
18. Nash K. Telbivudine in the treatment of chronic hepatitis B. Adv Ther 2009; 26: 155-169.
19. Bouchard MJ, Puro RJ, Wang L, Schneider RJ. Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J Virol 2003; 77: 7713-7719.
20. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 1987; 84: 1005-1009.
21. Zhou S, Standring DN. Hepatitis B virus capsid particles are assembled from core-protein dimer precursors. Proc Natl Acad Sci U S A 1992; 89: 10046-10050.
22. Radziwill G, Tucker W, Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNAse H activity. J Virol 1990; 64: 613-620.
23. Vergne-Salle P, Léger DY, Bertin P, Trèves R, Beneytout JL, Liagre B. Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. Cytokine 2005; 31: 335-348.
24. Leger DY, Liagre B, Beneytout JL. Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents. Apoptosis 2006; 11: 1747-1760.
25. Chang WW, Su IJ, Chang WT, Huang W, Lei HY. Suppression of p38 mitogen-activated protein kinase inhibits hepatitis B virus replication in human hepatoma cell: the antiviral role of nitric oxide. J Viral Hepat 2008; 15: 490-497.
26. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-3290.
27. Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. J Hepatol 2010; 52: 282-284.
28. Henklova P, Vrzal R, Papouskova B, Bednar P, Jancova P, Anzenbacherova E, et al. SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes. Eur J Pharmacol 2008; 593: 16-23.
29. Huang M, Wang Y, Collins M, Graves LM. CPEC induces erythroid differentiation of human myeloid leukemia K562 cells through CTP depletion and p38 MAP kinase. Leukemia 2004; 18: 1857-1863.
30. Tarn C, Zou L, Hullinger RL, Andrisani OM. Hepatitis B virus X protein activates the p38 mitogen-activated protein kinase pathway in dedifferentiated hepatocytes. J Virol 2002; 76: 9763-9772.
31. Yun C, Cho H, Kim SJ, Lee JH, Park SY, Chan GK, et al. Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway. Mol Cancer Res 2004; 2: 159-169.
32. Zheng Y, Li J, Ou JH. Regulation of hepatitis B virus core promoter by transcription factors HNF1 and HNF4 and the viral X protein. J Virol 2004; 78: 6908-6914.
33. Guo H, Gao C, Mi Z, Zhang J, Kuo PC. Characterization of the PC4 binding domain and its interactions with HNF4alpha. J Biochem 2007; 141: 635-640.
34. Li J, Ou JH. Differential regulation of hepatitis B virus gene expression by the Sp1 transcription factor. J Virol 2001; 75: 8400-8406.
35. D'Addario M, Arora PD, McCulloch CA. Role of p38 in stress activation of Sp1. Gene 2006; 379: 51-61.
36. Gong ZJ, De Meyer S, Clarysse C, Verslype C, Neyts J, De Clercq E, et al. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat 1999; 6: 229-236.
37. Wu J, Xie HY, Jiang GP, Xu X, Zheng SS. The effect of mycophenolate acid on hepatitis B virus replication in vitro. Hepatobiliary Pancreat Dis Int 2003; 2: 410-413.
38. Ying C, Colonno R, De Clercq E, Neyts J. Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir. Antiviral Res 2007; 73: 192-196.
39. Maes BD, van Pelt JF, Peeters JC, Nevens F, Evenepoel P, Kuypers D. The effect of mycophenolate mofetil on hepatitis B viral load in stable renal transplant recipients with chronic hepatitis B. Transplantation 2001; 72: 1165-1166.
40. Sayarlioglu H, Erkoc R, Dogan E, Sayarlioglu M, Topal C. Mycophenolate mofetil use in hepatitis B associated-membranous and membranoproliferative glomerulonephritis induces viral replication. Ann Pharmacother 2005; 39: 573.